Vnitr Lek 2016, 62(2):125-133

The rational diagnostic of cholangiocarcinoma

Martin Rydlo1,*, Jana Dvořáčková2, Tomáš Kupka1, Pavel Klvaňa1, Jaroslav Havelka3, Magdalena Uvírová4, Edvard Geryk5, Daniel Czerný3, Tomáš Jonszta3, Martina Bojková1, Vladimír Hrabovský1, Veronika Jelínková1, Arnošt Martínek1, Petr Dítě1
1 Interní klinika LF OU a FN Ostrava
2 Ústav patologie LF OU a FN Ostrava
3 Ústav radiodiagnostický LF OU a FN Ostrava
4 CGB laboratoř, Ostrava
5 Oddělení pro vědu a výzkum FN Brno

Cholangiocarcinoma (CC) is a rare malignant tumour arising from cholangiocytes, and its prognosis is usually unfavourable, mostly as a result of late diagnosis of the tumour. The current incidence of cholangiocarcinoma in the Czech Republic is 1.4/100,000 inhabitants per year; in less than 30 % of patients with CC, one of the known risk factors can be identified, most frequently, primary sclerosing cholangitis. Only patients with early diagnosed and surgically amenable cholangiocarcinoma are likely to have a longer survival time; in their case, survival for more than five years has been achieved in 20 % to 40 %. From the perspective of the need for early diagnosis of CC, a significant part is played by imaging and histopathologic evaluation; the early diagnostic significance of oncomarkers is limited. The rational early diagnosis of CC consists in effective use of differentiated advantages of different imaging modalities - MRI with DSA appears to be the optimal method, endosonography is a sensitive method for the identification of malignancy in the hepatic hilum or distal common bile duct, MRCP (magnetic resonance cholangiopancreatography) is used to display pathological changes in the biliary tree, ERCP (endoscopic retrograde cholangiopancreatography) allows material removal for histopathological examination. Other new approaches are also beneficial, such as IDUS - intraductal ultrasonography of biliary tract or SPY-GLASS, enabling examination of the bile ducts by direct view with the possibility of taking targeted biopsies. Sensitivity and specificity of histology and cytology can be increased by using the molecular cytogenetic FISH method, i.e. fluorescence in situ by hybridization, with a specificity of 97 %.

Keywords: epidemiology; cholangiokarcinoma; rational diagnostic; risk factors

Received: July 29, 2015; Accepted: October 15, 2015; Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rydlo M, Dvořáčková J, Kupka T, Klvaňa P, Havelka J, Uvírová M, et al.. The rational diagnostic of cholangiocarcinoma. Vnitr Lek. 2016;62(2):125-133.
Download citation

References

  1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liv Dis 2004; 24(2): 115-125. Go to original source... Go to PubMed...
  2. Patel T. Increase incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33(6): 1353-1357. Go to original source... Go to PubMed...
  3. Shaib YH, Davila JA, Mc Glynn K et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40(3): 472-477. Go to original source... Go to PubMed...
  4. Taylor-Robinson SD, Toledano MB, Arora S et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48(6): 816-820. Go to original source... Go to PubMed...
  5. ÚZIS. Novotvary ČR 1991-2010. Zdravotnická statistika. Ediční řada. ÚZIS ČR: Praha. Dostupné z WWW: <http://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary>.
  6. Blechacz B, Komuta M, Roskams T et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8(9): 512-522. Go to original source... Go to PubMed...
  7. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54(1): 173-184. Go to original source... Go to PubMed...
  8. Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005; 366(9493): 1303-1314. Erratum in Lancet 2006; 367(9523): 1656. Go to original source... Go to PubMed...
  9. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10(2): 77-82. Go to original source... Go to PubMed...
  10. Khan SA, Davidson BR, Goldin RD et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61(12): 1657-1669. Go to original source... Go to PubMed...
  11. Adenugba A, Khan SA, Taylor-Robinson SD et al. Polychlorinated biphenyls in bile of patients with biliary tract cancer. Chemosphere 2009; 76(6): 841-846. Go to original source... Go to PubMed...
  12. Claessen MM, Vleggaar FP, Tytgat KM et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50(1): 158-164. Go to original source... Go to PubMed...
  13. Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer 2009; 40(1-2): 19-25. Go to original source... Go to PubMed...
  14. Bismuth H, Castaing D. Hepatobiliary malignancy. Edward Arnold: London 1994.
  15. Deoliveira ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53(4): 1363-1371. Go to original source... Go to PubMed...
  16. Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248(1): 84-96. Go to original source... Go to PubMed...
  17. Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51(Suppl 6): VI1-VI9. Go to original source... Go to PubMed...
  18. Skipworth JR, Keane MG, Pereira SP. Update on the management of cholangiocarcinoma. Dig Sci 2014; 32(5): 570-578. Go to original source... Go to PubMed...
  19. Ehrmann J, Hůlek P et al. Hepatologie. Grada: Praha 2014: 602-604. ISBN 978-80-247-5510-6.
  20. Patel AH, Harnois DM, Klee GG et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patiens without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95(1): 204-207. Go to original source... Go to PubMed...
  21. Bonney GK, Craven RA, Prasad R et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008; 9(2): 149-158. Go to original source... Go to PubMed...
  22. Hultcrantz R, Olsson R, Danielsson A et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30(4): 669-673. Go to original source... Go to PubMed...
  23. Charatcharoenwitthaya P, Enders FB, Halling KC et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48(4): 1106-1117. Go to original source... Go to PubMed...
  24. Ghazale A, Chari ST, Zhang L et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134(3): 706-715. Go to original source... Go to PubMed...
  25. Kuszyk BS, Soyer P, Bluemke DA et al. Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. Crit Rev Diagn Imaging 1997; 38(1): 59-88.
  26. Kluge R, Schmidt F, Caca K et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33(5): 1029-1035. Go to original source... Go to PubMed...
  27. Kim JY, Kim MH, Lee TY et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008; 103(5): 1145-1151. Go to original source... Go to PubMed...
  28. Maccioni F, Martinelli M, Al Ansari N et al. Magnetic resonance cholangiography: past, present and future: a review. Eur Rev Med Pharmacol Sci 2010; 14(8): 721-725. Go to PubMed...
  29. Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139(7): 547-557. Go to original source... Go to PubMed...
  30. Corvera CU, Blumgart LH, Akhurst T et al. 18F-Fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206(1): 57-65. Go to original source... Go to PubMed...
  31. Furukawa H, Ikuma H, Asakura K et al. Prognostic importace of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol 2009; 100(6): 494-499. Go to original source... Go to PubMed...
  32. Weynand B, Deprez P. Endoscopic ultrasound guided fine needle aspiration in biliary and pancreatic diseases: pitfalls and performances. Acta Gastroenterol Belg 2004; 67(3): 294-300. Go to PubMed...
  33. Chen YK, Parsi MA, Binmoeller KF et al. Single-operator cholangioscopy in patiens requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 2011; 74(4): 805-814. Go to original source... Go to PubMed...
  34. Sharma AK. Role of MRCP versus ERCP in bile duct cholangiocarcinoma and benign stricture. Biomed Imaging Interv J 2007; 3(1): e12-e545.
  35. DeWitt J, Misra VL, Leblanc JK et al. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 2006; 64(3): 325-333. Go to original source... Go to PubMed...
  36. Urban O, Arnelo U, Kliment M et al. Cholangiopankreatoskopie pomocí SpyGlassTM direct visualization system: seznámení s metodou a první vlastní zkušenosti. Gastroent Hepatol 2013; 67(2): 124-126.
  37. Bosman FT, Carneiro F, Hruban RH et al. WHO classification of tumours of the digestive system. 4th ed. IARC: Lyon 2010. ISBN 9789283224327.
  38. Akiba J, Nakashima O, Hattori S et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37(4): 496-505. Go to original source... Go to PubMed...
  39. Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol 1998; 15(4): 285-299.
  40. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37(5): 961-969. Go to original source... Go to PubMed...
  41. Honsová E. Úloha patologa v diagnostice a léčbě onemocnění v hepatobiliární oblasti. Bulletin HPB 2004; 12(1-2): 1-2.
  42. Honsová E. Histopatologická diagnóza hepatocelulárního karcinomu. Gastroent Hepatol 2012; 66(2): 93-98.
  43. Levy MJ, Baron TH, Clayton AC et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminace bile duct strictures. Am J Gastroenterol 2008; 103(5): 1263-1273. Go to original source... Go to PubMed...
  44. Gonda TA, Glick MP, Sethi A et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc 2012; 75(1): 74-79. Go to original source... Go to PubMed...
  45. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Dostupné z WWW: <http://atlasgeneticsoncology.org/>
  46. Cheng L, Eble JN. Molecular surgical patology. Springer: New York 2013. ISBN 978-1461448990. Go to original source...
  47. Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis 2014; 32(5): 564-569. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.